Autopsy report · NCT00655668
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
Cause of deathFunding or business
“Decision not to pursue as single agent in the study population.”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 2 years 1 month before it stopped.
- 54 participants enrolled.
- Results were posted on the registry 1 year 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Celgene
- Sponsor type
- Industry
- Conditions
- T-cell Non-Hodgkin's Lymphoma
- Interventions
- Lenalidomide
- Participants
- 54
- Sites
- 45
- Countries
- Australia, Belgium, France, United States
Trials that died the same way
- Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid
“The Investigator decided not to pursue this study.” - Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
“The study team decided not to pursue this study.” - Genes Mutation Pentalogy of Cantrell
“Physician's chose to not follow through with the study.” - Assessment of Thoughts and Feelings Occurring During and After a Meal
“Decision was made not to start the study before it was initiated.” - A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
“A decision was made to not move forward with the study. No participants were enrolled or treated.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.